Back
Memory-hub-Souvenaid-Liquid-Range-724x1024-v1

Souvenaid Liquid

A food for special medical purposes that nutritionally supports memory function during the early stages of Alzheimer’s disease.

  • Clinically Proven: Nutritionally supports memory function in early Alzheimer’s.1-3
  • Research: Backed by 20 years of pre-clinical and clinical research.1-4
  • Well tolerated: Alone or in combination with Alzheimer’s disease medication.1-4
Request product for evaluation Download Product Factsheet

Product Information

A food for special medical purposes that nutritionally supports memory function during the early stages of Alzheimer’s disease.

Link copied!
Flavour

Vanilla (24x125ml bottles), Strawberry (24x125ml bottles), Cappuccino (24x125ml bottles).

Indications

For the dietary management of Alzheimer’s disease. To be used as a supplement to the normal dietary intake.

Important Notice
  • Not suitable as a sole source of nutrition.
  • Not for intravenous use.
  • Not suitable for patients with allergies to fish oil, milk or soy
  • Not suitable for patients with galactosaemia.
  • Souvenaid does contain carbohydrate and as with other foods containing carbohydrate, it is advisable for people with diabetes to monitor their blood glucose levels as per normal.
Direction for Use
  • Souvenaid is designed to be taken as one bottle (125ml) once a day, in addition to the normal dietary intake.
  • The length of use of Souvenaid by an individual should be determined by their healthcare professional.
  • Shake well before use.
  • Ready to drink and best served chilled.
Storage
  • Store in a cool, dry place.
  • Once opened, store in the refrigerator.
  • Discard unused content after 24 hours.
Product Type

Oral Nutritional Supplements.

Age Group

Adult

Brand

Souvenaid

References
  1. Scheltens P et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement 2010; 6(1): 1–10.e1.
  2. Scheltens P et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis 2012; 31(1): 225–36.
  3. Soininen H et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16: 965–75
  4. Shah RC et al. The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease. Alzheimers Res Ther 2013; 5: 59.